nicorandil has been researched along with No-Reflow Phenomenon in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, N; Pang, W; Ren, L; Xu, L; Zou, D | 1 |
| Gao, MD; Li, XW; Liu, Y; Liu, YY; Sun, GY; Xiao, JY; Zhang, EY | 1 |
| An, S; Huang, H; Jiang, Y; Wang, H | 1 |
| Pang, Z; Yao, Z; Zhao, W | 1 |
| Chen, T; Jiang, Z; Niu, J; Qi, Q; Wang, T; Yin, H | 1 |
| Chen, X; Chen, Z; Dong, X; Fu, X; Huo, X; Li, S | 1 |
| Eshraghi, A; Nezafati, MH; Nezafati, P; Sani, HD; Shahri, B; Vojdanparast, M | 1 |
| Monassier, JP | 1 |
| Date, M; Fujii, K; Higuchi, Y; Imai, M; Inoue, K; Ito, H; Ito, N; Iwakura, K; Kimura, R; Koyama, Y; Kubota, A; Nagai, H; Okamura, A; Okazaki, Y; Ozawa, M; Shibuya, M; Suenaga, H; Toyoshima, Y | 1 |
| Bernal, JM; Cubeddu, RJ; Don, CW; Kiernan, GD; Kiernan, TJ; Ruggiero, NJ; Witzke, C; Yan, BP | 1 |
| Iwamoto, K; Morishige, K; Sadamatsu, K; Shikada, T; Tanaka, H; Tashiro, H; Tokunou, T; Yoshida, K; Yoshidomi, Y | 1 |
| Fujiwara, Y; Ikeda, T; Kobatake, R; Saito, H; Sato, T; Sunami, H; Ujihira, T; Yoshioka, R | 1 |
| Gao, RL; Pei, WD; Sun, YH; Yang, YJ; Zhai, M; Zhang, YH; Zhao, JL | 1 |
4 review(s) available for nicorandil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Aged; Coronary Circulation; Female; Humans; Male; Middle Aged; Nicorandil; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Treatment Outcome; Vasodilator Agents | 2021 |
Reperfusion injury in acute myocardial infarction: from bench to cath lab. Part II: Clinical issues and therapeutic options.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Animals; Coronary Circulation; Electrocardiography; Heart Conduction System; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Nicorandil; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombectomy; Treatment Outcome; Vasodilator Agents | 2008 |
Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis.
Topics: Aged; Cardiovascular Agents; Combined Modality Therapy; Coronary Circulation; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Nicorandil; No-Reflow Phenomenon; Publication Bias; Recovery of Function; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2009 |
The no-reflow phenomenon in the coronary circulation.
Topics: Adenosine; Animals; Coronary Circulation; Diltiazem; Humans; Nicardipine; Nicorandil; Nitroprusside; No-Reflow Phenomenon; Prostheses and Implants; Vasodilator Agents; Verapamil | 2009 |
4 trial(s) available for nicorandil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Injections; Male; Middle Aged; Nicorandil; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Treatment Outcome; Vasodilator Agents; Young Adult | 2021 |
Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Blood Pressure; Cardiotonic Agents; Coronary Disease; Creatine Kinase, MB Form; Diastole; Elective Surgical Procedures; Female; Heart Rate; Humans; Male; Malondialdehyde; Middle Aged; Nicorandil; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Peroxidase; Stroke Volume; Systole; Troponin I | 2017 |
Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
Topics: Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicorandil; No-Reflow Phenomenon; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction | 2018 |
Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial.
Topics: Adult; Aged; Angina Pectoris; Canada; Coronary Angiography; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Nicorandil; Nitroglycerin; No-Reflow Phenomenon; Single-Blind Method; Treatment Outcome; Vasodilator Agents | 2015 |
5 other study(ies) available for nicorandil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Pressure; Blood Pressure; Coronary Circulation; Female; Hemodynamics; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Nicorandil; No-Reflow Phenomenon; Percutaneous Coronary Intervention | 2020 |
Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow.
Topics: Aged; Anti-Arrhythmia Agents; Colorimetry; Coronary Angiography; Echocardiography, Doppler; Endothelin-1; Female; Heart; Humans; Male; Middle Aged; Nicorandil; Nitric Oxide; No-Reflow Phenomenon; Radioimmunoassay | 2015 |
Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Circulation; Female; Humans; Isosorbide Dinitrate; Male; Middle Aged; Nicorandil; No-Reflow Phenomenon; Prospective Studies; Vasodilator Agents | 2010 |
Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Circulation; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Nicorandil; Nitroprusside; No-Reflow Phenomenon; Time Factors; Treatment Outcome; Vasodilator Agents | 2011 |
Intravenous nicorandil preserves endothelial junctions by decreasing endothelin-1 via activation of ATP-sensitive K+ channel.
Topics: Animals; Antigens, CD; Cadherins; Coronary Vessels; Disease Models, Animal; Endothelial Cells; Endothelin-1; Glyburide; Injections, Intravenous; Intercellular Junctions; KATP Channels; Ligation; Myocardial Infarction; Myocardium; Nicorandil; No-Reflow Phenomenon; Potassium Channel Blockers; Research Design; Swine; Swine, Miniature; Vasodilator Agents | 2007 |